Seelos Therapeutics, Inc.
SEEL · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $2 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $30 | $0 | $0 | $0 |
| Gross Profit | -$28 | -$0 | $0 | $0 |
| % Margin | -1,267.1% | – | – | – |
| R&D Expenses | $30 | $59 | $47 | $11 |
| G&A Expenses | $13 | $12 | $15 | $8 |
| SG&A Expenses | $13 | $12 | $15 | $8 |
| Sales & Mktg Exp. | -$0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $13 | $71 | $62 | $19 |
| Operating Income | -$40 | -$71 | -$62 | -$19 |
| % Margin | -1,838.4% | – | – | – |
| Other Income/Exp. Net | $3 | -$3 | -$4 | -$0 |
| Pre-Tax Income | -$38 | -$74 | -$66 | -$19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$38 | -$76 | -$68 | -$19 |
| % Margin | -1,719.6% | – | – | – |
| EPS | -7.73 | -21.48 | -22.29 | -12.88 |
| % Growth | 64% | 3.6% | -73.1% | – |
| EPS Diluted | -7.73 | -21.48 | -22.29 | -12.88 |
| Weighted Avg Shares Out | 5 | 4 | 3 | 1 |
| Weighted Avg Shares Out Dil | 5 | 4 | 3 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $2 | $0 |
| Depreciation & Amortization | $0 | $0 | $62 | $19 |
| EBITDA | -$38 | -$73 | $0 | $0 |
| % Margin | -1,713.6% | – | – | – |